| Daratumumab, lenalidomide, and dexamethasone for multiple myeloma MA Dimopoulos, A Oriol, H Nahi, J San-Miguel, NJ Bahlis, SZ Usmani, ... New England Journal of Medicine 375 (14), 1319-1331, 2016 | 1575 | 2016 |
| Targeting CD38 with daratumumab monotherapy in multiple myeloma HM Lokhorst, T Plesner, JP Laubach, H Nahi, P Gimsing, M Hansson, ... New England Journal of Medicine 373 (13), 1207-1219, 2015 | 1279 | 2015 |
| Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a … JF San-Miguel, VTM Hungria, SS Yoon, M Beksac, MA Dimopoulos, ... The lancet oncology 15 (11), 1195-1206, 2014 | 891 | 2014 |
| Daratumumab plus lenalidomide and dexamethasone for untreated myeloma T Facon, S Kumar, T Plesner, RZ Orlowski, P Moreau, N Bahlis, S Basu, ... New England Journal of Medicine 380 (22), 2104-2115, 2019 | 869 | 2019 |
| Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma SZ Usmani, BM Weiss, T Plesner, NJ Bahlis, A Belch, S Lonial, ... Blood, The Journal of the American Society of Hematology 128 (1), 37-44, 2016 | 495 | 2016 |
| International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment MA Dimopoulos, P Sonneveld, N Leung, G Merlini, H Ludwig, E Kastritis, ... Journal of Clinical Oncology 34 (13), 1544-1557, 2016 | 435 | 2016 |
| Teclistamab in relapsed or refractory multiple myeloma P Moreau, AL Garfall, NWCJ van de Donk, H Nahi, JF San-Miguel, A Oriol, ... New England Journal of Medicine 387 (6), 495-505, 2022 | 418 | 2022 |
| Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label … PG Richardson, A Oriol, M Beksac, AM Liberati, M Galli, F Schjesvold, ... The Lancet Oncology 20 (6), 781-794, 2019 | 349 | 2019 |
| Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study SK Kumar, MA Dimopoulos, E Kastritis, E Terpos, H Nahi, H Goldschmidt, ... Leukemia 31 (11), 2443-2448, 2017 | 319 | 2017 |
| Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components E Alici, T Sutlu, B Björkstrand, M Gilljam, B Stellan, H Nahi, HC Quezada, ... Blood, The Journal of the American Society of Hematology 111 (6), 3155-3162, 2008 | 243 | 2008 |
| Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 … MV Mateos, H Nahi, W Legiec, S Grosicki, V Vorobyev, I Spicka, ... The lancet haematology 7 (5), e370-e380, 2020 | 206 | 2020 |
| American society of blood and marrow transplantation, european society of blood and marrow transplantation, blood and marrow transplant clinical trials network, and … S Giralt, L Garderet, B Durie, G Cook, G Gahrton, B Bruno, P Hari, ... Biology of Blood and Marrow Transplantation 21 (12), 2039-2051, 2015 | 205 | 2015 |
| Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised … T Facon, SK Kumar, T Plesner, RZ Orlowski, P Moreau, N Bahlis, S Basu, ... The Lancet Oncology 22 (11), 1582-1596, 2021 | 196 | 2021 |
| Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group P Moreau, SK Kumar, J San Miguel, F Davies, E Zamagni, N Bahlis, ... The Lancet Oncology 22 (3), e105-e118, 2021 | 192 | 2021 |
| Genome-wide association study identifies multiple susceptibility loci for multiple myeloma JS Mitchell, N Li, N Weinhold, A Försti, M Ali, M Van Duin, G Thorleifsson, ... Nature communications 7 (1), 12050, 2016 | 183 | 2016 |
| Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial UH Mellqvist, P Gimsing, O Hjertner, S Lenhoff, E Laane, K Remes, ... Blood, The Journal of the American Society of Hematology 121 (23), 4647-4654, 2013 | 176 | 2013 |
| Teclistamab, a B-cell maturation antigen× CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm … SZ Usmani, AL Garfall, NWCJ van de Donk, H Nahi, JF San-Miguel, ... The Lancet 398 (10301), 665-674, 2021 | 173 | 2021 |
| European perspective on multiple myeloma treatment strategies in 2014 H Ludwig, P Sonneveld, F Davies, J Bladé, M Boccadoro, M Cavo, ... The oncologist 19 (8), 829-844, 2014 | 149 | 2014 |
| Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia S Deneberg, M Grövdal, M Karimi, M Jansson, H Nahi, A Corbacioglu, ... Leukemia 24 (5), 932-941, 2010 | 144 | 2010 |
| Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor T Sutlu, B Stellan, M Gilljam, HC Quezada, H Nahi, G Gahrton, E Alici Cytotherapy 12 (8), 1044-1055, 2010 | 139 | 2010 |
Saad Z. UsmaniChief of Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NYVerified email at mskcc.org
